Influenza vaccination and use of lipid lowering therapies in adults with atherosclerotic cardiovascular disease: An analysis of the Behavioral Risk Factor Surveillance System (BRFSS) - 18/01/24
, Adam N. Berman, MD a, b, Prakriti Gaba, MD a, b, Rosangela A. Hoshi, PhD a, b, Murray A. Mittleman, MD, DrPH b, c, dABSTRACT |
Background |
Influenza vaccination and lipid lowering therapy (LLT) are evidence-based interventions with substantial benefit for individuals with established atherosclerotic cardiovascular disease (ASCVD). However, levels of influenza immunization and LLT use are low, possibly due to pervasive fear-based misinformation uniquely targeting vaccines and LLT. Whether being unvaccinated for influenza predicts lower utilization of LLT is unknown.
Objectives |
We tested the hypothesis that American adults with ASCVD who are unvaccinated for influenza have lower use of LLT even after accounting for traditional factors associated with underuse of preventive therapies.
Methods |
We pooled 2017, 2019, and 2021 survey data from the Behavioral Risk Factor Surveillance System (BRFSS), and selected respondents aged 40 to 75 years with self-reported ASCVD. We used logistic regression models adjusted for potential confounders to examine the association between influenza vaccination and self-reported LLT use. We performed a sensitivity analysis with multiple imputation to account for missing data. All analyses accounted for complex survey weighting.
Results |
Of 66,923 participants with ASCVD, 55% reported influenza vaccination in the last year and 76% reported using LLT. Being unvaccinated for influenza was associated with lower odds of LLT use (OR 0.54; 95% CI 0.50, 0.58; P< .001). In a multivariable regression model adjusting for demographics and comorbidities, this association remained statistically significant (aOR 0.58, 95% CI 0.52, 0.64, P < .001). After additional adjustment for preventive care engagement, health care access, and use patterns of other cardiovascular medications this association persisted (aOR 0.66; 95% CI 0.60, 0.74; P < .001). There were no significant differences across subgroups, including those with and without hyperlipidemia.
Conclusions |
Unvaccinated status for influenza was independently associated with 34% lower odds of LLT use among American adults with ASCVD after adjustment for traditional factors linked to underuse of preventive therapies. This finding identifies a population with excess modifiable ASCVD risk, and supports investigation into nontraditional mechanisms driving underuse of preventive therapies, including fear-based misinformation.
Le texte complet de cet article est disponible en PDF.GRAPHICAL ABSTRACT |
Abbreviations : ASCVD, BRFSS, CI, OR
Plan
Vol 268
P. 1-8 - février 2024 Retour au numéro
Article précédent
- Design and rationale of the evaluation of transcatheter aortic valve replacement compared to surveillance for patients with asymptomatic severe aortic stenosis: The EARLY TAVR trial
- Philippe Généreux, Allan Schwartz, Brad Oldemeyer, David J. Cohen, Björn Redfors, Heather Prince, Yanglu Zhao, Brian R. Lindman, Philippe Pibarot, Martin B. Leon
- Trends in mortality risk of patients with congenital heart disease during the COVID-19 pandemic
- Yanxu Yang, Kristina Kuo, J'Neka S. Claxton, Jessica H. Knight, Yijian Huang, Matthew E. Oster, Lazaros K. Kochilas
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?